Diffusion tensor imaging reveals changes in non-fat infiltrated muscles in late onset Pompe disease

Robert Rehmann1, Martijn Froeling2, Marlena Rohm1

  • 1Department of Neurology, Heimer Institute for Muscle Research, BG-University Hospital Bergmannsheil, Ruhr-University Bochum, Bochum, Germany.

Muscle & Nerve
|July 13, 2020
PubMed

Insights

Muscle diffusion tensor imaging (mDTI) detects early structural changes in late-onset Pompe disease (LOPD) muscles, even before significant fat infiltration occurs. These MRI findings correlate with patient mobility, aiding disease monitoring.

Area of Science:

  • Biomedical Imaging
  • Neuromuscular Disorders
  • Radiology

Background:

  • Late-onset Pompe disease (LOPD) is a progressive neuromuscular disorder.
  • Magnetic Resonance Imaging (MRI) is valuable for monitoring LOPD progression.
  • Early detection of muscle changes is crucial for LOPD management.

Purpose of the Study:

  • To assess muscle diffusion tensor imaging (mDTI) for detecting alterations in LOPD patients.
  • To investigate mDTI in LOPD muscles with less than 10% fat fraction.
  • To correlate mDTI findings with functional assessments like the 6-Minute Walk Test (6-MWT).

Main Methods:

  • Evaluated thigh and calf muscles in 18 LOPD patients and 29 healthy controls using a 3T MRI scanner.
  • Acquired mDTI, T1w, and mDixonquant sequences to quantify diffusion parameters (MD, RD, FA, λ1-3) and fat fraction.
  • Correlated diffusion metrics with 6-MWT results.

Main Results:

  • Significant differences in diffusion parameters were observed between LOPD patients and healthy controls (P < .05).
  • Thigh muscles with <10% fat infiltration showed significant alterations in MD, RD, and λ1-3.
  • Mean diffusivity (MD) demonstrated a positive correlation with 6-MWT performance (P = .06).

Conclusions:

  • Muscle diffusion tensor imaging (mDTI) effectively reveals diffusion restrictions in LOPD muscles.
  • mDTI identifies structural muscle changes preceding fatty degeneration in LOPD.
  • mDTI shows potential as a sensitive imaging biomarker for LOPD progression.